Trotter M J, Acker B D, Chaplin D J
Medical Biophysics Unit, B.C. Cancer Research Centre, Vancouver, Canada.
Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):785-9. doi: 10.1016/0360-3016(89)90067-9.
The effect of the vasodilator hydralazine on tumor vascular function has been evaluated in C3H/He mice bearing subcutaneously implanted SCCVII squamous cell carcinoma. Changes in microregional perfusion following hydralazine administration were observed using a double fluorescent staining technique. Hydralazine-induced alterations in tumor blood flow were measured using laser Doppler flowmetry. The results obtained indicate that hydralazine causes a dose-dependent reduction in functional tumor vasculature implying complete flow stasis and/or vascular collapse in some vessels. Fifteen minutes after a dose of 10 mg/kg intravenously, perfusion in 36 +/- 5% (SEM) of tumor vessels was completely abolished. In addition to cessation of perfusion in individual vessels, hydralazine eliminated flow in large patches of vasculature distributed non-uniformly throughout the tumor. Hydralazine (10 mg/kg i.v.) resulted in a 67 +/- 5% (SEM) reduction in tumor red blood cell (RBC) flow as measured by laser Doppler techniques. The mean number of moving red blood cells declined by 35 +/- 8%, suggesting a reduction in microvascular volume. These results support the hypothesis that following hydralazine administration, perfusion stops completely in some blood vessels probably as a result of vascular collapse or flow stasis.
在皮下植入SCCVII鳞状细胞癌的C3H/He小鼠中，评估了血管扩张剂肼屈嗪对肿瘤血管功能的影响。使用双重荧光染色技术观察了肼屈嗪给药后微区域灌注的变化。使用激光多普勒血流仪测量了肼屈嗪引起的肿瘤血流变化。获得的结果表明，肼屈嗪导致功能性肿瘤血管系统呈剂量依赖性减少，这意味着一些血管中完全血流停滞和/或血管塌陷。静脉注射10mg/kg剂量后15分钟，36±5%（标准误）的肿瘤血管灌注完全消失。除了个别血管灌注停止外，肼屈嗪还消除了分布在整个肿瘤中不均匀的大片血管区域的血流。通过激光多普勒技术测量，肼屈嗪（静脉注射10mg/kg）导致肿瘤红细胞（RBC）血流减少67±5%（标准误）。移动红细胞的平均数量下降了35±8%，表明微血管容积减少。这些结果支持了以下假设：在给予肼屈嗪后，一些血管中的灌注可能由于血管塌陷或血流停滞而完全停止。
